Skip to main content
Premium Trial:

Request an Annual Quote

Quark Biotech to Supply AstraZeneca with Cancer Targets

NEW YORK, Oct. 3 - Quark Biotech said Wednesday that it would use its gene and protein function profiling technology to supply AstraZeneca with potential cancer targets.

Under the terms of the deal, Quark, a Cleveland-based company that conducts most of its research in Israel, will provide AstraZeneca of London with 100 genes and proteins it identifies using its platform, known as BiFAR. The companies will also work together to evaluate and validate the function of these potential targets.

"AstraZeneca is determined to maintain its leading position in the discovery and development of novel agents targeted at the underlying mechanisms that distinguish tumor cells from normal cells," Les Hughes, vice president of global cancer research at AstraZeneca, said in a statement.

“The collaboration with QBI gives us the opportunity to identify rapidly exciting targets that are aberrant in tumor cells and hence could form the basis of future drug hunting programs,” he said.

AstraZeneca will also have the right to license target genes and proteins for product development. QBI will retain the rights to any targets AstraZeneca does not pursue.

In exchange for its research services, QBI will receive research and development funding of an undisclosed sum as well as milestone payments and product royalties.

AstraZeneca has exclusive rights to commercialize products generated from the collaboration.

Quark Biotech seeks to determine which genes and proteins are involved in a disease by focusing on key events underlying a disease and reconstructing it in tissue culture. The functional profiling platform does not require knowledge of gene sequence. 

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.